Trutankless, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Trutankless, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $242.4K | Aug 28, 2025 |
| FY2024 | Dec 31, 2023 | $3.5K | Aug 28, 2025 |
| FY2023 | Dec 31, 2022 | $73.0K | May 20, 2025 |
| FY2022 | Dec 31, 2021 | $246.0K | Nov 15, 2023 |
| FY2021 | Dec 31, 2020 | $1.66M | Nov 30, 2022 |
| FY2020 | Dec 31, 2019 | $1.91M | Jun 24, 2021 |
| FY2019 | Dec 31, 2018 | $1.54M | Apr 23, 2020 |
| FY2018 | Dec 31, 2017 | $695.9K | Apr 10, 2019 |
| FY2017 | Dec 31, 2016 | $429.6K | Apr 16, 2018 |
| FY2016 | Dec 31, 2015 | $265.5K | Jul 26, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($37.0K) | Aug 28, 2025 |
| FY2024 | Dec 31, 2023 | $3.5K | Aug 28, 2025 |
| FY2023 | Dec 31, 2022 | ($393.9K) | May 20, 2025 |
| FY2022 | Dec 31, 2021 | $118.4K | Nov 15, 2023 |
| FY2021 | Dec 31, 2020 | $356.3K | Nov 30, 2022 |
| FY2020 | Dec 31, 2019 | $177.4K | Jun 24, 2021 |
| FY2019 | Dec 31, 2018 | ($165.7K) | Apr 23, 2020 |
| FY2018 | Dec 31, 2017 | $165.3K | Apr 10, 2019 |
| FY2017 | Dec 31, 2016 | ($60.7K) | Apr 16, 2018 |
| FY2016 | Dec 31, 2015 | ($77.5K) | Jul 26, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($10.19M) | Aug 28, 2025 |
| FY2024 | Dec 31, 2023 | ($2.15M) | Aug 28, 2025 |
| FY2023 | Dec 31, 2022 | ($4.78M) | May 20, 2025 |
| FY2022 | Dec 31, 2021 | ($17.38M) | Nov 15, 2023 |
| FY2021 | Dec 31, 2020 | ($10.57M) | Nov 30, 2022 |
| FY2020 | Dec 31, 2019 | ($4.89M) | Jun 24, 2021 |
| FY2019 | Dec 31, 2018 | ($3.54M) | Apr 23, 2020 |
| FY2018 | Dec 31, 2017 | ($2.87M) | Apr 10, 2019 |
| FY2017 | Dec 31, 2016 | ($3.27M) | Apr 16, 2018 |
| FY2016 | Dec 31, 2015 | ($4.29M) | Jul 26, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($5.22M) | Aug 28, 2025 |
| FY2024 | Dec 31, 2023 | ($1.34M) | Aug 28, 2025 |
| FY2023 | Dec 31, 2022 | ($4.16M) | May 20, 2025 |
| FY2022 | Dec 31, 2021 | ($11.04M) | Nov 15, 2023 |
| FY2021 | Dec 31, 2020 | ($6.89M) | Nov 30, 2022 |
| FY2020 | Dec 31, 2019 | ($3.34M) | Jun 24, 2021 |
| FY2019 | Dec 31, 2018 | $2.89M | Apr 23, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $432.8K | Aug 28, 2025 |
| FY2024 | Dec 31, 2023 | $432.6K | Aug 28, 2025 |
| FY2023 | Dec 31, 2022 | $255.1K | May 20, 2025 |
| FY2022 | Dec 31, 2021 | $211.0K | Nov 15, 2023 |
| FY2021 | Dec 31, 2020 | $187.6K | Nov 30, 2022 |
| FY2020 | Dec 31, 2019 | $417.2K | Jun 24, 2021 |
| FY2019 | Dec 31, 2018 | $216.1K | Apr 23, 2020 |
| FY2018 | Dec 31, 2017 | $165.2K | Apr 10, 2019 |
| FY2015 | Dec 31, 2015 | $318.7K | Nov 3, 2016 |
| FY2015 | Dec 31, 2014 | $876.8K | Nov 3, 2016 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $683 | Nov 15, 2023 |
| FY2021 | Dec 31, 2021 | $10.62M | Nov 30, 2022 |
| FY2021 | Dec 31, 2020 | $6.79M | Nov 30, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($2.32M) | Aug 28, 2025 |
| FY2024 | Dec 31, 2023 | ($1.99M) | Aug 28, 2025 |
| FY2023 | Dec 31, 2022 | ($1.71M) | May 20, 2025 |
| FY2022 | Dec 31, 2021 | ($2.43M) | Nov 15, 2023 |
| FY2021 | Dec 31, 2020 | ($1.47M) | Nov 30, 2022 |
| FY2017 | Dec 31, 2017 | ($1.52M) | Apr 16, 2018 |
| FY2017 | Dec 31, 2016 | ($1.41M) | Apr 16, 2018 |
| FY2016 | Dec 31, 2015 | ($2.52M) | Jul 26, 2017 |
| FY2015 | Dec 31, 2014 | ($2.73M) | Nov 3, 2016 |
| FY2014 | Dec 31, 2013 | ($458.6K) | Apr 1, 2015 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $191.9K | Aug 28, 2025 |
| FY2024 | Dec 31, 2023 | $0 | Aug 28, 2025 |
| FY2022 | Dec 31, 2022 | $0 | Nov 15, 2023 |
| FY2022 | Dec 31, 2021 | $25.3K | Nov 15, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Nov 30, 2022 |
| FY2019 | Dec 31, 2019 | $0 | Apr 23, 2020 |
| FY2019 | Dec 31, 2018 | $892 | Apr 23, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Apr 10, 2019 |
| FY2016 | Dec 31, 2015 | $1.2K | Jul 26, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $3.40M | Aug 28, 2025 |
| FY2024 | Dec 31, 2023 | $255.8K | Aug 28, 2025 |
| FY2023 | Dec 31, 2022 | $207.0K | May 20, 2025 |
| FY2022 | Dec 31, 2021 | $228.8K | Nov 15, 2023 |
| FY2021 | Dec 31, 2020 | $1.80M | Nov 30, 2022 |
| FY2020 | Dec 31, 2019 | $927.2K | Jun 24, 2021 |
| FY2019 | Dec 31, 2018 | $870.8K | Apr 23, 2020 |
| FY2018 | Dec 31, 2017 | $702.3K | Apr 10, 2019 |
| FY2017 | Dec 31, 2016 | $509.8K | Apr 16, 2018 |
| FY2016 | Dec 31, 2015 | $857.4K | Jul 26, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $9.74M | Aug 28, 2025 |
| FY2024 | Dec 31, 2023 | $7.80M | Aug 28, 2025 |
| FY2023 | Dec 31, 2022 | $5.74M | May 20, 2025 |
| FY2022 | Dec 31, 2021 | $4.12M | Nov 15, 2023 |
| FY2021 | Dec 31, 2020 | $4.16M | Nov 30, 2022 |
| FY2020 | Dec 31, 2019 | $3.95M | Jun 24, 2021 |
| FY2019 | Dec 31, 2018 | $2.83M | Apr 23, 2020 |
| FY2018 | Dec 31, 2017 | $2.14M | Apr 10, 2019 |
| FY2017 | Dec 31, 2016 | $1.14M | Apr 16, 2018 |
| FY2016 | Dec 31, 2015 | $1.12M | Jul 26, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($6.35M) | Aug 28, 2025 |
| FY2024 | Dec 31, 2023 | ($7.54M) | Aug 28, 2025 |
| FY2024 | Dec 31, 2022 | ($5.53M) | Aug 28, 2025 |
| FY2023 | Dec 31, 2021 | ($3.89M) | May 20, 2025 |
| FY2022 | Dec 31, 2020 | ($2.36M) | Nov 15, 2023 |
| FY2021 | Dec 31, 2019 | ($3.03M) | Nov 30, 2022 |
| FY2019 | Dec 31, 2018 | ($1.96M) | Apr 23, 2020 |
| FY2018 | Dec 31, 2017 | ($1.43M) | Apr 10, 2019 |
| FY2017 | Dec 31, 2016 | ($626.6K) | Apr 16, 2018 |
| FY2016 | Dec 31, 2015 | ($267.0K) | Jul 26, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | ($77.10M) | Aug 28, 2025 |
| FY2024 | Dec 31, 2023 | ($66.92M) | Aug 28, 2025 |
| FY2023 | Dec 31, 2022 | ($64.77M) | May 20, 2025 |
| FY2022 | Dec 31, 2021 | ($60.37M) | Nov 15, 2023 |
| FY2021 | Dec 31, 2020 | ($42.99M) | Nov 30, 2022 |
| FY2020 | Dec 31, 2019 | ($32.43M) | Jun 24, 2021 |
| FY2019 | Dec 31, 2018 | ($27.53M) | Apr 23, 2020 |
| FY2018 | Dec 31, 2017 | ($24.00M) | Apr 10, 2019 |
| FY2017 | Dec 31, 2016 | ($21.07M) | Apr 16, 2018 |
| FY2016 | Dec 31, 2015 | ($17.80M) | Jul 26, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $79.5K | Nov 15, 2023 |
| FY2022 | Dec 31, 2021 | $20.8K | Nov 15, 2023 |
| FY2020 | Dec 31, 2020 | $151.6K | Jun 24, 2021 |
| FY2020 | Dec 31, 2019 | $4.3K | Jun 24, 2021 |
| FY2020 | Dec 31, 2018 | $9.7K | Jun 24, 2021 |
| FY2019 | Dec 31, 2017 | $78.6K | Apr 23, 2020 |
| FY2018 | Dec 31, 2016 | $87.1K | Apr 10, 2019 |
| FY2017 | Dec 31, 2015 | $3.6K | Apr 16, 2018 |
| FY2016 | Dec 31, 2014 | $40.4K | Jul 26, 2017 |
| FY2014 | Dec 31, 2013 | $1.3K | Apr 1, 2015 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | 0 | Apr 10, 2019 |
| FY2018 | Dec 31, 2017 | 0 | Apr 10, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Apr 16, 2018 |
| FY2016 | Dec 31, 2015 | 0 | Jul 26, 2017 |
| FY2015 | Dec 31, 2014 | 0 | Nov 3, 2016 |
| FY2014 | Dec 31, 2013 | 0 | Apr 1, 2015 |
| FY2013 | Dec 31, 2012 | 0 | Apr 14, 2014 |
| FY2012 | Dec 31, 2011 | 0 | Apr 16, 2013 |
| FY2011 | Dec 31, 2010 | (2) | May 2, 2012 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 0 | Aug 28, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Aug 28, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 128.61M | Aug 28, 2025 |
| FY2024 | Dec 31, 2023 | 38.77M | Aug 28, 2025 |
| FY2023 | Dec 31, 2022 | 20.37M | May 20, 2025 |
| FY2022 | Dec 31, 2021 | 20.22M | Nov 15, 2023 |
| FY2021 | Dec 31, 2020 | 9.23M | Nov 30, 2022 |
| FY2017 | Dec 31, 2017 | 27.92M | Apr 16, 2018 |
| FY2017 | Dec 31, 2016 | 23.72M | Apr 16, 2018 |
| FY2016 | Dec 31, 2015 | 19.35M | Jul 26, 2017 |
| FY2013 | Dec 31, 2013 | 8.15M | Apr 14, 2014 |
| FY2013 | Dec 31, 2012 | 8.15M | Apr 14, 2014 |